#None #Haemonetics #EQT Life Sciences #Vivasure Medical

EQT Life Sciences Exits Vivasure Medical via Haemonetics Acquisition

EQT Life Sciences has announced a significant transition, marking its exit from Vivasure Medical Limited through a strategic sale to Haemonetics Corporation, a prominent name in the medical technology field. This acquisition is expected to bolster Haemonetics' offerings in the market, particularly in advanced closure technologies.

Overview of the Acquisition

Vivasure Medical, based in Galway, Ireland, has been at the forefront of developing innovative solutions in percutaneous vessel closure. The highlight of their technological advancements is the PerQseal® Elite system, which features a unique bioabsorbable patch designed to seal large access sites within arteries or veins from the inside. This approach provides a sutureless solution for various structural heart and endovascular procedures.

The acquisition includes an initial cash payment of EUR 100 million, with the potential for an additional EUR 85 million based on specific sales milestones and growth targets. This structure underscores the confidence that both parties have in the future of the product and its anticipated success in the marketplace.

Historical Context

EQT Life Sciences first invested in Vivasure in 2016, participating in the company’s Series C funding round. The support provided was instrumental in the company's journey through critical stages of clinical development and regulatory approvals, culminating in a Premarket Approval application submitted to the U.S. Food and Drug Administration (FDA) in 2025. Additionally, the product received CE Mark approval in Europe for both arterial and venous applications, signaling its readiness for international markets.

Anne Portwich, a Partner at EQT Life Sciences, expressed pride in her role on Vivasure's board, emphasizing the firm’s commitment to supporting innovations that enhance patient care through better treatment options. Portwich stated, “Supporting companies with products that make better treatments available to patients lies at the core of our health economics strategy.”

Insights from Leadership

Andrew Glass, the CEO of Vivasure Medical, conveyed his enthusiasm regarding the acquisition, noting the collaborative efforts among clinicians, employees, and investors that paved the way for Vivasure's advancements in closure technology. He highlighted that joining Haemonetics would provide the necessary global resources to accelerate the distribution and implementation of the PerQseal Elite technology, thereby benefiting a broader range of physicians and patients globally.

In a related statement, Ken Crowley, the Vice President and General Manager of Interventional Technologies at Haemonetics, remarked that this acquisition enhances their existing portfolio with clinically differentiated technologies. He pointed out that with the compelling clinical performance data of PerQseal Elite, this acquisition positions Haemonetics to solidify its leadership role in the advanced closure device market.

Implications for the Future

The transaction not only reflects the growing importance of innovative medical technologies in modern healthcare but also highlights the expanding role of venture capital in nurturing breakthrough developments. As EQT Life Sciences exits its investment in Vivasure, it leaves behind a legacy of innovation that is set to continue under the Haemonetics umbrella. This acquisition is expected to enhance the availability of vital medical solutions that could transform procedures in structural heart and endovascular interventions, thereby improving patient outcomes and care standards worldwide.

As the healthcare landscape continues to evolve with innovative technologies, Haemonetics' acquisition of Vivasure Medical stands as a testament to the potential of collaboration and strategic partnerships in driving forward the mission of enhanced patient care.